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1. Introduction  
Phosphatase and tension homolog deleted on chromosome 10, PTEN, is a tumor suppressor gene 
that is responsible for controlling tumorigenesis in various organs (Li and Sun 1997, Steck et 
al. 1997, Li et al. 1997, Ali, Schriml and Dean 1999). Functionally, PTEN exhibits 
phospholipid phosphatase activity and negatively regulates the conversion of 
phosphatidylinositol 4, 5-diphosphate (PIP2) to PIP3 (Stambolic et al. 1998, Wu et al. 1998). 
PTEN ablation results in the accumulation of PIP3, which recruits AKT to the cell 
membrane, where PIP3-dependent protein kinase-1 (PDK1) and mammalian target of 
rapamycin (mTOR) complex 2 (mTORC2), also known as the Rictor-mTOR complex, 
activate and phosphorylate AKT at amino acid residues Thr308 and Ser473, respectively 
(Alessi et al. 1997, Sarbassov et al. 2004, Sarbassov et al. 2005). Consequently, activated AKT 
acts as a key effector and modulates a variety of downstream signal regulators. One AKT-
targeting protein is tuberous sclerosis complex 2 (TSC2) (Inoki et al. 2002, Manning et al. 
2002), which is a GTPase-activating protein that forms a complex with TSC1 to block a small 
GTPase Rheb at GDP-bound status, consequently resulting in mTORC1 (the Raptor-mTOR 
complex) inhibition. Thus, AKT-mediated TSC1-TSC2 inhibition results in mTORC1 
activation, which promotes cell growth and protein translation partly through 
phosphorylating S6 kinase (S6K) and the eIF-4E-binding protein 1 (4E-BP1) (Brunn et al. 
1997, Hara et al. 1997, Brown et al. 1995). Activated mTORC1 and S6K can also regulate 
PI3K-AKT signaling through a negative feedback mechanism [see Fig 1; reviewed in 
(Carracedo and Pandolfi 2008, Manning and Cantley 2007)]. In addition, activated AKT can 
target glycogen synthase kinase 3 (GSK3) (Cross et al. 1995), -catenin (Fang et al. 2007, He 
et al. 2007), double minute 2 (Mdm2) (Mayo and Donner 2001, Zhou et al. 2001b), p21 (Zhou 
et al. 2001a), p27 (Fujita et al. 2002), forkhead-related transcription factors (Brunet et al. 
1999), Bcl2-antagonist of cell death (Datta et al. 1997, Peso et al. 1997), and other genes, 
leading to cellular proliferation, anti-apoptosis, survival, and tumorigenesis [see Fig 1; 
(Cully et al. 2006, Kishimoto et al. 2003, Manning and Cantley 2007, Dunlop and Tee 2009)]. 
To model Pten-deficient malignancies, conditional Pten mutant alleles have been generated 
in mice. Using tissue-specific Cre-loxP-mediated Pten gene excision, the roles of Pten have 
been intensively studied across multiple organs in mice. We previously used an inducible 
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Cre under the control of a ubiquitous promoter, ROSA26 (R26), to examine the susceptibility 
of all tissues to Pten-deficient tumorigenesis in an adult mice strain referred to as R26-
Ptenfx/fx. We found that lymphomas accounted for the majority of Pten-deficient 
malignancies (Lu et al. 2007). However, the high incidence and short latency of lymphomas 
in the R26-Ptenfx/fx mice limited our analyses of the tumors arising from the epithelial tissues, 
the most common origin of human cancers. To address the susceptibility of epithelial tissues 
to Pten loss, we performed spatiotemporally controlled Pten excision by using a newly 
generated inducible Cre transgene driven by the keratin 8 (K8) promoter in a mouse strain 
referred to as K8-Ptenfx/fx. In this epithelial Pten-deficient mouse, multiple epithelial tumors 
arose, and they could be monitored at different time points after Pten was ablated. 
 
 
Fig. 1. Schematic illustration of PTEN/PI3K/AKT and their downstream effectors. 
2. Genetic tool for conditional genetic manipulation in the epithelial tissues  
To develop transgenic mice expressing inducible Cre (CreERT) in epithelial tissues, we 
generated and characterized the transgenic mouse line Tg(K18-EGFP, K8-CreERT), in which the 
visualized enhanced green fluorescence protein (EGFP) is driven by the K18 upstream 
regulatory elements and the CreERT fusion gene is driven by K8 (Fig 2). To evaluate the 
induced CreERT recombinase activity after tamoxifen (Tam) administration, Tg(K18-EGFP,K8-
CreERT) mice, hereafter abbreviated as K18-EG/K8-CE, were bred with ROSA26 Cre reporter 
(R26RLacZ/+) mice (Soriano 1999) to generate K18-EG/K8-CEtg/+;R26RLacZ/+ bigenic mice.  
We monitored K18 promoter-directed EGFP expression in the offspring of C57BL/6 females, 
which were bred with different lines of K18-EG/K8-CE males. We found that lines B, G, and 
H among eight transgenic lines exhibited strong and consistent EGFP signals in the tail, 
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footpads, and all internal organs lined by simple epithelium (data not shown). 
Subsequently, these three lines were selected to breed with R26RLacZ/+ mice to generate 
double-transgenic mice (referred to K18-EG/K8CEtg/+;R26RLacZ/+), which were evaluated by 
whole mount X-gal staining of inducible CreERT recombinase expression driven by the K8 
upstream sequence. At 5-6 weeks of age, Tam was intraperitoneally administered to K18-
EG/K8CEtg/+;R26RLacZ/+ bigenic and control (R26RLacZ/+) mice, after which we examined inducible 
Cre activity by assessing X-gal staining, which reflected LacZ expression at 10 days after Tam 
treatment. We found that similar LacZ expression patterns were observed among the B, G, and H 
lines on the R26RLacZ/+ background.  
2.1 Evaluation of inducible Cre activity of K18-EG/K8-CEtg/+; R26RLacZ/+ bigenic mice 
across multiple organs  
In the lower respiratory tract of bigenic mice, EGFP- and X-gal-positive staining was clearly 
observed in the trachea, bronchi, and bronchioles, but not in the alveoli (Fig 2BB’ and CC’). 
Histological sections of X-gal-stained tissues revealed that inducible Cre activity was mainly 
restricted in the pseudostratified epithelial cells of the terminal bronchiole (TB) (Fig 2C’) that 
expressed K8, which colocalized with EGFP fluorescence driven by the K18 upstream 
sequence (Fig 1B’), but Cre activity was not observed in the pneumocyte lining of the 
alveolar sac (AS) (Fig 2B and C). In the liver of bigenic mice, intense EGFP- and X-gal-
positive staining revealed the organization of bile ducts or gross portal tracts (Fig 2D and E). 
Intense EGFP- and X-gal-positive staining was also visualized in the gallbladder (GB, Fig 2D 
and E). Through histological analysis and immunofluorescence staining using an antibody 
against K8, we found that intense K8 and EGFP expression was detected in the intrahepatic 
bile duct (BD) compared with that in the surrounding hepatocytes (Fig 2D’). Intensely X-gal-
stained cells were mainly observed in the epithelial lining of the intrahepatic BD (Fig 2E’) 
and gallbladder (data not shown). Furthermore, bright EGFP-positive and intense X-gal-
positive signals could be easily visualized in the pancreas, but not in the adjacent spleen (Fig 
2F and G), of bigenic mice. Microscopically, pancreatic ducts (PDs) and exocrine acini 
expressed EGFP and K8 (Fig 2F’), which colocalized with X-gal staining (Fig 2G’).  
Along the gastrointestinal tract of bigenic mice, the hind-stomach and intestine also 
exhibited bright EGFP fluorescence (Fig 2H and J) and the intense blue X-gal staining 
indicative of LacZ expression (Fig 2I and K). Immunostaining using an antibody against K8, 
together with EGFP fluorescence, revealed that both K8 and EGFP expression appeared in 
the epithelial cells of the hind stomach (Fig 2H’) and small intestine (Fig 2J’). Tam-induced 
LacZ expression was detected in the lower portion of zymogenic and parietal cells in the 
glandular hind stomach (Fig 2I’) and in crypts of the small intestine (Fig 2K’).  
We further examined EGFP and induced LacZ expression in the reproductive tracts of 
bigenic mice (Fig 3). In the male reproductive tract, the seminal vesicles (SVs; Fig 3A and B) 
and epididymis (Fig 3E and F) exhibited intense EGFP expression and X-gal staining, 
whereas the testis exhibited neither LacZ nor EGFP expression (Fig 3E and F). In the 
prostate, the ventral prostate (VP) lobes and dorsolateral prostate (DLP) lobes exhibited 
strong LacZ and EGFP expression (Fig 3C and D) compared to that in the anterior prostate 
(AP) lobes (Fig 2A and B). Immunostaining of K8 was colocalized with EGFP fluorescence in 
the epithelial lining of the SV (Fig 3A’), the VP (Fig 3C’) and epididymis (Fig 3E’). In 
addition, the histological sections revealed X-gal-positive staining in the epithelia of 
corresponding organs (Fig 3B’, D’, and F’). Notably, patchy EGFP and X-gal signals partly 
overlapped with K8-expressing luminal cells of the AP (Fig 3A” and B’’), indicative of 
inefficient expression of EGFP and LacZ in the AP of bigenic mice.  
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Fig. 2. Evaluation of the visualization marker EGFP and inducible Cre activity of Tg(K18-
EGFP, K8-CreERT) mice. (A) Schematic illustration of the genetic tool, Tg(K18-EGFP,  
K8-CreERT) referred to K18-EG/K8-CE, which exhibits EGFP expression under the control  
of the K18 promoter and inducible Cre activity driven by the K8 promoter, which was 
evaluated by the Cre reporter allele, R26RlacZ, after tamoxifen (Tam) administration. (B-K) 
Visualization of EGFP and evaluation of Tam-induced Cre-loxP recombination activity in 
the dissected organs of K18-EG/K8-CEtg/+;R26RLacZ/+ mice treated with Tam for 10 days. (B) 
Whole-mount EGFP expression was visualized in the trachea, bronchus, and bronchiole of 
the K18-EG/K8-CEtg/+;R26RLacZ/+ lung. (B’) EGFP and immunofluorescent staining of K8 (red) 
revealed the colocalization of EGFP and K8 in the bronchiole columnar epithelium but not 
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in the AS. DAPI staining was used to indicate the nuclei. (C) The presence of LacZ 
expression was indicated by X-gal-stained epithelial tissues that had similar staining profiles 
as the EGFP-expressing tissue of the K18-EG/K8-CEtg/+;R26RLacZ/+ lung in (B). (C’) A 
histological section of the X-gal-stained lung was counterstained with Nuclear Fast Red to 
detect X-gal-stained epithelial cells. Insets in (B’) and (C’), high magnification of the 
epithelium of the terminal bronchiole (TB); (D) Intense EGFP expression was visualized as 
branching portal tracts in the K18-EG/K8CEtg/+;R26RLacZ/+ liver. GB, gallbladder; L, left liver 
lobe; M, medial liver lobe; (D’) EGFP and K8 expression was strongly detected in bile ducts 
(BDs) residing close to the portal vein (PV) and weakly detected in hepatocytes. CV, central 
vein; (E) Intense X-gal-positive blue patterns were similar to the EGFP expression patterns 
in the GB and branching portal tracts, but only patchy staining was observed in the liver 
parenchyma. (E’) Sections of whole-mount X-gal-stained liver exhibited strong blue staining 
in the BD. (F) and (G) Intense EGFP expression and the presence of LacZ were detected in 
the pancreas but not in the spleen (Spl). (F’) EGFP and K8 expression as positively detected 
in the exocrine acini and pancreatic ducts (PDs). (G’) Homogenous blue staining was 
histologically observed in the pancreatic acini and PDs. (H) and (I) Intense EGFP- and X-gal-
positive staining was observed in the hind-stomach (HS), but not in the forestomach (FS). 
(H’) and (I’) EGFP and LacZ expression were highly localized at the base of the glandular 
stomach. (J) and (J’) Epithelial cells of the small intestine (jejunum) exhibited a strong EGFP 
signal. (K) and (K’) Mosaic LacZ activity revealed by X-gal staining in the crypts and upper 
differentiated epithelium of the jejunum. Scale bar, 100 μm. 
In the reproductive tract of our bigenic females, EGFP was detected in the K8-expressing 
simple epithelium of the oviduct and uterus (Fig 3GG’ and II’). However, mosaic X-gal-
positive patterns were observed in the simple epithelium of the oviduct and uterine glands 
(Fig 3 H’ and J’). Unexpectedly, LacZ and EGFP expression was not detected either grossly 
(Fig 3 G and H) or microscopically (Fig 3G’ and H’) in the ovarian surface epithelium (OSE; 
data not shown), which was thought to be the K8/K18-expressing cell type. The lack of 
EGFP and inducible LacZ expression in the OSE of bigenic mice indicated that the cis-
regulatory elements within the K8-K18 intergenic sequence are unable to drive EGFP and 
CreERT expression in the OSE.  
2.2 Temporally controlled fate mapping to evaluate epithelial turnover in the 
mammary luminal epithelium and intestinal epithelium  
In the adult stage, epithelial cell turnover is required to ensure the long-term maintenance of 
epithelial tissue homeostasis, which may be dysregulated during tumorigenesis. The process 
for epithelial renewal through generating new cells, differentiation, and migration from 
their stem/progenitors and niche varies among different epithelial tissues (Blanpain, 
Horsley and Fuchs 2007). As our K18-EG/K8-CEtg/+;R26RLacZ/+ mice were administered Tam 
by intraperitoneal injection at 6 weeks of age, we could monitor LacZ expression in various 
epithelial organs at different time points to determine whether inducible Cre activity 
occurred in higher hierarchical K8-expressing stem/progenitors to continuously give rise to 
their descendants. If the inducible Cre activity occurred in the stem/progenitors, then 
permanent LacZ activity could be detected in their descendants during cell turnover. In 
contrast, if the Tam-induced LacZ-expressing cells are terminally differentiated cells, then 
the LacZ-positive cells may be replaced by newly generated cells in which the loxP-flanked 
stop cassette of the R26R allele is not excised, indicating that these cells arise from K8-
independent epithelial progenitors.  
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Fig. 3. EGFP visualization and evaluation of Tam-induced Cre activity in the reproductive 
organs of K18-EG/K8-CEtg/+;R26RLacZ/+ mice treated with Tam for 10 days. (A) and (B) The 
seminal vesicle (SV) exhibits greater EGFP and LacZ expression than the anterior prostate 
(AP). (A’) and (B’) Histological sections revealed an intensive EGFP signal (green) 
coexpressed with K8- (red) and X-gal-stained LacZ-expressing epithelia. (A’’) and (B’’) 
Histological sections revealed a weak mosaic EGFP signal (green) coexpressed with K8 (red) 
and few X-gal-stained cells, indicative of poor inducible Cre activity in the AP. (C) and (D) 
Whole-mount EGFP and LacZ were present in the bladder and prostate [ventral prostate 
(VP) and dorsolateral prostate (DLP)]. (C’) and (D’) Sections revealed intense EGFP and K8 
coexpressing cells and X-gal-stained epithelia in the VP. (E) and (F) Intense EGFP- and X-
gal-positive staining was clearly detected in the epididymis but not in the testis. (E’) and (F’) 
Histological sections of the epididymis exhibited an intense EGFP signal (green) 
coexpressed with K8 and LacZ activity. (G-J) In the female reproductive tract, an intense 
EGFP signal was observed in the oviduct (OD) and uterus (U), whereas X-gal staining was 
more strongly detected in the uterus. (G’-J’) Sections exhibited EGFP and K8 coexpression in 
the epithelia of the oviduct (G’) and uterus (I’), whereas mosaic X-gal-stained epithelia were 
observed in the corresponding organs (H’) and (J’). Scale bar, 100 μm. 
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Fig. 4. Intestinal and mammary epithelial turnover monitored by LacZ activity in K18-
EG/K8-CEtg/+;R26RLacZ/+ mice. (A) Partial X-gal staining was detected in the intestines 
(jejunum) of the B line-derived K18-EG/K8-CEtg/+;R26RLacZ/+ mice in the absence of Tam 
administration (vehicle treatment) after 10 days. (B-D) After Tam administration for 10, 21, 
and 42 days, intense X-gal staining patterns were clearly detected in the K18-EG/K8-
CEtg/+;R26RLacZ/+ intestines. (A’-D’) Histological sections of the aforementioned samples were 
counterstained with Nuclear Fast Red, and they exhibited continuous X-gal-stained 
epithelial cells that emerged from the lower crypts to the upper absorptive cells in the K18-
EG/K8-CEtg/+;R26RLacZ/+ mice treated with Tam (B’-D’) for 10-42 days. Conversely, a few X-
gal-positive cells were detected in the intestines of vehicle-treated mice, indicating the leaky 
expression of LacZ. (E-H) Lower and (E’-H’) higher magnification of X-gal-stained fourth 
mammary fat pads revealed the presence of X-gal-stained branching ducts in K18-EG/K8-
CEtg/+;R26RLacZ/+ mammary glands after Tam treatment for 10, 21, and 42 days (FF’-HH’), 
whereas no X-gal-stained cells were detected in the absence of Tam (EE’). (E’’-H’’) 
Histological sections of the aforementioned mammary samples were counterstained with 
Nuclear Fast Red, and they exhibited X-gal-stained luminal epithelia (F’’-H’’) in a time-
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dependent manner in comparison to the staining in the vehicle control. (I) Timeline for the 
lineage tracing of a lactating mammary gland. The K18-EG/K8-CEtg/+;R26RLacZ/+ female was 
treated with Tam at 6 weeks of age and followed for 3 weeks to set up mating, and then the 
animal was analyzed at 1 week postparturition. (J-M) The dissected K18-EG/K8-
CEtg/+;R26RLacZ/+ mammary gland was visualized by EGFP expression (J-L) and LacZ activity 
(K-M) both grossly and histologically. (L) Lactating alveolar epithelia of mammary glands 
exhibited uniform EGFP expression and mosaic patchy LacZ expression. Nuclei were 
counterstained with DAPI. (M) Histology sections were counterstained with Nuclear Fast Red, 
and they exhibited a mosaic pattern of X-gal-stained epithelial cells in the lactating mammary 
gland. Scale bars of A-D, E-H, and E’-H’, 0.25 cm; Scale bars of E’’-H’’ and L-M, 100 μm. 
Complete epithelial turnover in the intestine requires approximately 5 days [for review, see 
(van der Flier and Clevers 2009)]. Conversely, the relatively slower turnover rate of mammary 
epithelial cells is regulated by the estrous cycle, and these cells undergo alveolar 
morphogenesis during pregnancy and lactation. Thus, we selectively monitored inducible 
LacZ activity in intestinal and mammary epithelia at 10, 21, and 42 days after Tam 
administration. In the absence of Tam administration (vehicle control), spotty X-gal signals 
were detected in the small intestine (Fig 4AA’), which indicated a leakage of inducible CreERT 
activity, resulting in rare but detectable levels of LacZ expression. After 10 days of Tam 
administration, X-gal-stained intestinal epithelia were detected in the cell lineage that emerged 
from the crypts, differentiated, and migrated upward to the villi (Fig 4BB’). This phenomenon 
was also observed after 21 and 42 days of induction (Fig 4CC’ and DD’), indicating that the K8-
expressing epithelia are composed of stem/progenitor cells that have the capability for long-
term intestinal maintenance. In contrast, the numbers of X-gal-stained ductal cells in 
mammary glands gradually reduced after Tam treatment for 21 and 42 days (Fig 4G-G’’and H-
H’’) compared to the number of X-gal-stained cells after 10 days of Tam treatment (Fig 4F). 
This observation suggests that the Tam-induced LacZ-expressing cells are replaced by newly 
generated cells from K8-independent epithelial origins, which give rise to LacZ-negative 
luminal cells that subsequently replace previous LacZ-positive cells to maintain mammary 
gland homeostasis. 
3. Characterization of Pten-deficient epithelial tumors  
3.1 The tumor latency, tumor spectrum, and tumor incidence of K18-EG/K8-CEtg/+; 
Ptenfx/fx mice 
Throughout intensive analyses of inducible Cre activity controlled by the K8 promoter in 
various epithelial tissues as shown in Section 2, we further monitored epithelial tumors 
arising from Pten-deficient epithelial tissues to clarify the susceptibility of different epithelia 
to Pten loss in multiple organs. Thus, we generated K18-EG/K8-CEtg/+;Ptenfx/+, K18-EG/K8-
CEtg/+;Ptenfx/fx (referred to K8-Ptenfx/+ and K8-Ptenfx/fx, respectively), and their littermate 
controls and induced Cre-loxP recombination using Tam to excise exon 5 of Pten as 
illustrated in Fig 5A. All mice were on a mixed B6/129/Balb/c background.  
Our results revealed that 92% of K8-Ptenfx/fx mice (23/25) and 26.3% of K8-Ptenfx/+ mice 
(5/19) developed various malignant tumors by 60 and 100 weeks after Tam treatment, 
respectively (Fig 5B). The cumulative cancer-free survival is presented in Fig 5B. The overall 
mean latency of Pten-deficient tumors was approximately 25 weeks. All tumors were 
primarily analyzed by gross appearance and H&E-stained histology. The malignant tumors 
that developed in K8-Ptenfx/fx and K8-Ptenfx/+ mice are summarized in Table 1.  
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We found that pancreatic ductal cancer (PDAC; 10 mice), cholangiocarcinoma (CC; 4 mice), 
hepatocellular carcinoma (HCC; 3 mice), and mammary gland tumors (MGTs; 7 females) 
accounted for the majority of the identified Pten-deficient malignancies (Fig 5C; Table 1), 
which are selectively described in Sections 3.2-3.4. Prostate cancer (two males) and 
precancerous lesions (prostate intraepithelial neoplasia) were also frequently found in K8-
Ptenfx/fx mice (data not shown). Other malignancies arising from the thyroid, lung, stomach, 
and uterus were occasionally identified in the K8-Ptenfx/fx mice (Table 1). In addition, 
multiple tumors arising from different organs were observed in K8-Ptenfx/fx mice (eight mice, 
32%; three males and five females; Table 1). Moreover, five different epithelial malignancies 
arising from the thyroid, lung, pancreas, intestine, and breast were found in five K8-Ptenfx/+ 
females. At present, no malignant tumors have been found in K8-Ptenfx/+ males, which may 
be due to the limited animal numbers (n=7); a higher number of K8-Ptenfx/+ males might be 
required for further confirmation.  
 
 
 
Fig. 5. Analysis of malignant tumors in the K8-Ptenfx/fx and K8-Ptenfx/+ mice. (A) Schematic 
illustration of the genetic tool, Tg(K18-EGFP, K8-CreERT), used to conditionally excise the 
Pten floxed allele after Tam administration. (B) Cancer-free survival of control, K8-Ptenfx/+, 
and K8-Ptenfx/fx mice. (C) Major epithelial malignancies (n>3) of K8-Ptenfx/fx mice. PDAC, 
pancreatic ductal cancer; CC, cholangiocarcinoma; HCC, hepatocellular carcinoma; MGT, 
mammary gland tumor.  
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*multiple tumors in 3 males and 5 females 
Table 1. Malignancies of the K8-Ptenfx/+ and K8-Ptenfx/fx mice. 
3.2 Pten-deficient pancreatic malignancies 
Among different tumor types, pancreatic malignancies developed approximately 12 weeks 
before other epithelial lesions, and pancreatic malignancies accounted for the majority of 
epithelial malignancies in Tam-treated K8-Ptenfx/fx mice (Fig 5C). Pancreata isolated from 
control mice (Fig. 6 A-C) and sick K8-Ptenfx/fx mice (Fig. 6 D-F, G-I, and J-L) were subjected to 
stereomicroscopy and histology. Grossly, the normal pancreas exhibited vasculature and a 
white appearance and was a soft organ connected to the caudal lobe of the liver, common 
bile duct, stomach, duodenum, and spleen (Fig. 6A). In the Pten-deficient pancreata, 
desmoplastic changes and cystic dilation could be identified (Fig. 6 D, G, and J). In addition, 
the higher EGFP intensity exhibited tubular or patchy patterns in the K8-Ptenfx/fx mutants 
(Fig. 6 E, H, and K; arrows) compared to the uniform GFP pattern of the control (Fig. 6B). 
Microscopically, interlobular ductal hyperplasia (Fig. 6F), acinar-to-ductal metaplasia (Fig. 
6I), and PDAC (Fig. 6L) were identified in some K8-Ptenfx/f mice. In our observations, PDAC 
progression in K8-Ptenfx/fx mice is an immediate life-threatening disease as like in humans. In 
general, our findings were consistent with an earlier report that characterized pancreatic 
ductal metaplasia and pancreatic cancer initiation in mice in which Pten was ablated by 
Pdx1-Cre starting from the developing pancreas specifically (Stanger et al. 2005). Our 
inducible Cre activity in the K8-expressing cells of the adult mouse pancreas likely includes 
pancreatic ducts and centroacinal cells in which Pten is excised, leading to PDAC. 
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Fig. 6. Pancreatic malignancy of the K8-Ptenfx/fx mice. Age-matched Tg(K18-EGFP, K8-CreER) 
pancreata were used as the control. Gross appearances and EGFP expression in control (A-
B) and K8-Ptenfx/fx pancreata (D-E, G-H, and J-K) were observed by stereomicroscopy. H&E-
stained histological sections of control pancreata revealed the exocrine acinar gland, 
pancreatic islet, interlobular duct, and blood vessel (C). Interlobular ductal hyperplasia (F), 
ductal metaplasia (I), and invasive pancreatic ductal adenocarcinoma (L) were histologically 
identified in the K8-Ptenfx/fx mice at 9-13 weeks after Tam treatment. Scale bar, 100 μm. 
3.3 Pten-deficient MGTs  
Previously, Li et al used a mammary-specific MMTV-Cre transgenic line to excise the loxP-
floxed Pten critical exon (exon 5) (Li et al. 2002). Some MMTV-Cre;Ptenfx/fx females develop 
MGTs as early as 2 months of age (Li et al. 2002). In our study, MGT was the most frequent 
(approximately 38.9%) malignancy in K8-Ptenfx/fx females (7/18 mice). Palpable MGTs were 
detected at 24-54 weeks (mean latency, 43 weeks) after Tam treatment (Fig 5C), and they 
were dissected and observed under a stereomicroscope. We found that EGFP-positive 
branches were clearly revealed in the control mammary gland, although the deeper 
mammary branches were shielded by thick adipose tissue (Fig 7A). In the K8-Ptenfx/fx 
mammary solid tumor, higher EGFP intensity was detected in a patchy pattern, which 
might represent a mass of hyperplastic epithelial cells (Fig 7B). Histologically, the 
representative Pten-deficient MGT was a solid epithelial mass with atypical glandular 
arrangement (Fig 7D) compared to the normal mammary ducts that were surrounded by 
adipose tissue (Fig 7C). To determine the effect of induced PTEN loss, we performed 
immunohistochemistry on the sections of the control and K8-Ptenfx/fx mammary tissues. Our 
results revealed that PTEN expression could be detected in various cells, including ductal 
luminal and basal epithelial cells, vascular endothelial cells, and stromal cells, within the 
control mammary gland (Fig 7E). In contrast, the loss of PTEN was specifically 
demonstrated in the epithelial tumor cells, but not in the neovascular endothelial cells and 
stromal cells, of K8-Ptenfx/fx MGTs (Fig 7F).  
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Fig. 7. Mammary tumors of the K8-Ptenfx/fx females. (A) Mammary fat pad with EGFP-
expressing ductal branches (inset) was obtained from a control female (42 weeks after Tam 
treatment); (B) MGT consisting of an EGFP-expressing tumor mass (inset) was obtained 
from a K8-Ptenfx/fx female (42 weeks after Tam treatment); (C) and (D) H&E-stained 
histological sections of control mammary tissue (C; 54 weeks after Tam treatment) and K8-
Ptenfx/fx MGT (D; 54 weeks after Tam treatment); (E) and (F) PTEN immunohistochemistry 
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revealed the induced loss of PTEN in a K8-Ptenfx/fx mammary epithelial tumor (F; 54 weeks 
after Tam treatment), whereas PTEN was expressed in various cell types within age-
matched control mammary tissue (arrows; E). Insets, high-power views of the PTEN levels 
in the control mammary duct (E) and mammary epithelial tumor (F); (G) and (H) 
Immunohistochemistry of p-Akt(Ser473) revealed cytoplasmic staining of p-Akt in tubular 
structures infiltrating within a stroma of a K8-Ptenfx/fx MGT (H; 35 weeks after Tam 
treatment) compared to a negatively stained mammary duct of an age-matched control 
mouse. Insets, high-power views of the p-Akt(Ser473) levels in the control mammary duct 
(G) and MGT (H). Scale bar (C-H), 100 μm. 
Then, we determined activation of AKT using antibody against phosphorylated AKT, p-
Akt(Ser473), and found that AKT phosphorylation appeared in the neoplastic epithelial cells 
of the K8-Ptenfx/fx MGT (Fig 7H), unlike the controls (Fig 7G).Thus, our data revealed that the 
mammary luminal epithelium was highly susceptible to Pten-deficient mammary 
tumorigenesis, although it might be replaced by a K8+-independent cell lineage as indicated 
by Cre reporter (LacZ) activity (Fig. 4E-H).  
3.4 Pten-deficient HCCs and intrahepatic CCs 
Liver-specific Pten ablation by albumin (Alb)-Cre has been reported to result in the 
development of steatohepatitis, metabolic disorders, and HCCs (Horie et al. 2004, Stiles et al. 
2004). According to two different reports, the latency of Pten-deficient hepatocellular 
carcinogenesis appears to be required for an extended time. Horie et al reported that Pten-
deficient HCCs developed in 66% of Alb-Cre;Ptenfx/fx animals at 74-78 weeks of age. Xu et al 
also found that the incidence of HCCs was 33% by 12-16 months of age (Xu et al. 2006). 
Interestingly, Xu et al reported that their Alb-Cre;Ptenfx/fx mice developed visible foci of CCs 
along with HCCs at late onset that were explained by the Alb-Cre mice exhibiting Cre 
activity in both hepatocytes and cholangiocytes (Xu et al. 2006). Moreover, early disease 
progression and higher penetrance of CCs were demonstrated when the Smad4 conditional 
allele was introduced into the Alb-Cre;Ptenfx/fx background (Xu et al. 2006).  
In our findings, low incidences of HCCs (3/25 mice) and CCs (4/25 mice) were identified 
in the Tam-treated K8-Ptenfx/fx mice at 9-54 (mean latency, 27 weeks) and 24-60 weeks 
(mean latency, 44 weeks), respectively (Fig 5C). Our observations indicated a longer 
period of disease progression for HCCs than for CCs after Pten loss was induced. 
However, the relative susceptibilities of hepatocytes and cholangiocytes to Pten-deficient 
tumorigenesis remain unclear because of the low incidence of both diseases. Moreover, 
the induced mosaic Cre recombination events in the hepatocytes compared to the uniform 
and intense reporter (LacZ) activity in the cholangiocytes of bile ducts as shown in Fig 2E 
should also be considered because differential induction of Cre activity may directly 
contribute to the differential pace of disease progression initiated in hepatocytes 
compared to that initiated in cholangiocytes. Nevertheless, we could identify both fatty 
accumulation in hepatocytes (Fig 8A) and dysplastic/hyperplastic cholangiocytes of the 
dilated bile ducts (Fig 8B) in the sections of K8-Ptenfx/fx livers at early time points (13 
weeks) after Tam treatment. These early events might directly or indirectly lead to HCC 
(Fig 8D) and CC, which could be identified by K19 expression (Fig 8F), in the Tam-treated 
K8-Ptenfx/fx mice at late onset. 
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Fig. 8. Liver diseases of the K8-Ptenfx/fx mice. (A) Fatty changes of hepatocytes in a K8-Ptenfx/fx 
mouse at 13 weeks after Tam treatment; (B) Aberrant dilated bile ducts (arrows) of the 
portal tract in a K8-Ptenfx/fx mouse at 13 weeks after Tam treatment; (C) H&E-stained section 
and gross view (C’, inset) of a control liver at 60 weeks after Tam treatment; (D) H&E-
stained section and gross view (D’, inset) of a K8-Ptenfx/fx liver at 60 weeks after Tam 
treatment; (E) and (F) K19 expressed in the control bile ductal cells (E) and in the acinar 
pattern of a representative K8-Ptenfx/fx CC (31 weeks). Scale bar, 100 μm.  
4. Conclusion 
In this chapter, we demonstrated that the mouse K8-K18 intergenic sequence possesses the 
essential promoters and regulatory elements for controlling the bidirectional expression of 
CreERT and EGFP across multiple organs. Selectively ablating the tumor suppressor gene 
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Pten in the epithelial cells of multiple organs in this study provides an entry point to 
understand epithelial tissue susceptibility to Pten-deficient tumorigenesis. Our data reveal 
that the K8-expressing epithelia of the pancreatic ducts, prostate, and mammary glands are 
highly susceptible to Pten-deficient tumorigenesis. Hepatocytes and cholangiocytes of the 
liver also possibly undergo tumorigenesis after Pten loss, which may evoke a variety of 
downstream signaling circuits. All Pten-deficient malignancies described here are primary 
tumors that invade locally. Metastasis is rare in our current observation that requires further 
characterization. In the future, the same approach can possibly be used to establish clinically 
relevant mouse models to investigate adenocarcinoma initiation and progression by 
simultaneously creating additional genetic lesions in conjunction with the K8-Ptenfx/+ or K8-
Ptenfx/fx alleles; mice that carry multiple conditional alleles of cancer-related genes can be 
generated and characterized to understand tumor susceptibility, considering that cancer is a 
disease of multiple genetic events.  
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